Aripiprazole: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Comprehensive categorization: +Third-Generation Antipsychotics |
MDElliottMD (talk | contribs) Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged. |
||
| Line 31: | Line 31: | ||
}} | }} | ||
[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]] | [[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]] | ||
[[Category:Neuroleptics]] | [[Category:Neuroleptics]] | ||
[[Category:Third-Generation Antipsychotics]] | [[Category:Third-Generation Antipsychotics]] | ||
Revision as of 18:00, 19 May 2026
Antipsychotic, Neuroleptic
Aripiprazole
Abilify
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Interactions
Pharmacogenomic + mechanism interactions
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
DPWG guideline: The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (DPWG) recommends reducing maximum dose of aripiprazole for patients carrying poor metabolizer alleles of CYP2D6.
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
Mechanism description, if it needs work:
Is this row worth surfacing?
Your own experience with this combination:
Experience (1 a little, 5 a lot)
Outcome (-100 worst, +100 best)
Patient experience
No patient-experience reports yet.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Antipsychotic, Neuroleptic
Common uses
Pharmacy
Pharmacology
Purported mechanism
D2/D3 partial agonist; 5-HT1A partial agonist; 5-HT2A antagonist